Dear Editor,
In the human body, magnesium (Mg) is absorbed by the small intestine and excreted from the kidneys under strict homeostatic regulation.1, 2 Long‐term administration of Mg‐losing diuretics and Mg‐containing agents under impaired Mg homeostasis leads to hypomagnesemia and hypermagnesemia, respectively. 3 Hypermagnesemia in older adults is caused mainly by the long‐term administration of Mg‐containing laxatives. Yamaguchi et al. reported a case series of hypermagnesemia induced by Mg oxide, and speculated that hypermagnesemia occurs more frequently than previously reported. 4 The main symptoms of hypermagnesemia described in their case series are non‐specific, including anorexia, weakness and drowsiness. Therefore, this pathological condition has attracted less clinical attention, but many physicians prescribe Mg‐containing laxatives without monitoring serum Mg concentrations. Based on such reality, Yamaguchi et al. concluded that senescence and renal insufficiency are the risk factors of hypermagnesemia in patients prescribed Mg oxide. 4 However, a cardiovascular manifestation of hypermagnesemia is not described in this literature. Here, we report an older patient with hypermagnesemia leading to heart failure (HF).
A 99‐year‐old demented, constipated and hypertensive man was introduced to Hara Doi Hospital, Fukuoka, Japan, due to the request for hospitalization by the nursing facility because of gradual hypotension (systolic blood pressure of 70–80 mmHg) and bradycardia (heart rate of 30–40 b.p.m.). On admission, he complained of general fatigue and anorexia, but showed no abnormal physical findings. Amlodipine (5.0 mg/day) and memantine (10 mg/day) were terminated. Blood pressure and heart rate were 110–46 mmHg and 44 b.p.m., respectively. Body temperature and SpO2 were 36.1°C and 98% at room air. Because blood chemistry showed anemia, renal dysfunction, elevated brain natriuretic peptide and hypermagnesemia, administration of Mg oxide (3000 mg/day, ×3) was terminated, sennoside was started as an alternative laxative, and drip infusion of potassium‐ and Mg‐free solution (500 mL/day) was initiated. The main physical and laboratory findings are shown in Table 1. Chest X‐ray showed cardiomegaly (cardiothoracic ratio of 62.0%), but no pulmonary congestion or effusion. Electrocardiogram on admission showed sinus bradycardia associated with second‐degree sinoatrial block (longest RR interval 1.8 s, and basic HR 36 b.p.m.), left axis deviation (QRS axis of −34°) and complete right bundle branch block. However, the sinoatrial block disappeared in an electrocardiogram recorded on the next day of admission. Echocardiogram recorded on that day showed an ejection fraction of 68%. The patient was discharged after confirming the restoration of hypermagnesemia.
Table 1.
Serial physical and laboratory findings in a 99‐year‐old male patient with heart failure
| Day X | Day X + 3 | Day X + 7 | Day X + 17 | Day X + 23 | ||
|---|---|---|---|---|---|---|
| Normal range | ||||||
| BP | 110–46 | 126–60 | 120–66 | 120–62 | 124–80 | |
| HR | 44 | 52 | 64 | 60 | 56 | |
| RBC | 435–555 | 305 | 307 | 287 | 322 | 349 |
| Hb | 13.7–16.8 | 9.1 | 9.6 | 8.9 | 9.9 | 10.8 |
| Ht | 40.7–50.1 | 30.4 | 29.9 | 28 | 31.7 | 34.5 |
| WBC | 3300–8600 | 5700 | 6200 | 5200 | 5100 | 5400 |
| Plt | 15.8–34.8 | 15.4 | 17.5 | 17.8 | 16.5 | 16.3 |
| TP | 6.6–8.1 | 6.9 | 6.7 | 7 | 7.1 | |
| Alb | 4.1–5.1 | 3.7 | 3.5 | 3.5 | 3.7 | |
| FBG | 73–109 | 107 | 94 | 94 | ||
| T. Chol | 142–248 | 138 | 148 | |||
| HDL | 38–90 | 48 | ||||
| LDL | 65–163 | 75 | ||||
| TG | 40–234 | 76 | 83 | |||
| UA | 3.7–7.8 | 6.4 | 5.2 | 6 | 6.6 | 8.4 |
| CK | 59–248 | 72 | 37 | 26 | 36 | |
| BUN | 8.0–20.0 | 33.2 | 26.5 | 39.6 | 53.2 | 56.3 |
| Cr | 0.65–1.07 | 3.02 | 2.32 | 2.44 | 2.48 | 2.79 |
| T. Bil | 0.4–1.5 | 0.6 | 0.7 | 0.6 | 0.5 | 0.6 |
| AST | 13–30 | 42 | 22 | 16 | 19 | 20 |
| ALT | 10–30 | 29 | 17 | 8 | 8 | 7 |
| ALP | 38–113 | 89 | 76 | 78 | 78 | |
| LDH | 124–222 | 215 | 166 | 151 | 158 | |
| CHE | 240–486 | 170 | ||||
| eGFR | >90 | 15.5 | 20.7 | 19.6 | 19.2 | 16.9 |
| eCCR | >90 | 7.8 | 10.7 | 10.2 | 9.3 | 7.9 |
| BNP | 0–18.4 | 1105.3 | ||||
| CRP | 0–0.14 | 0.05 | 0.21 | |||
| Na | 138–145 | 139 | 143 | 144 | 144 | 145 |
| K | 3.6–4.8 | 4.5 | 4.1 | 4.5 | 4.6 | 4.4 |
| Cl | 101–108 | 102 | 109 | 111 | 108 | 107 |
| Ca | 8.8–10.1 | 8.5 | ||||
| Mg | 1.8–2.4 | 5.1 | 4 | 2.6 | 3.1 | |
| Fe | 40–188 | 66 | ||||
| Zn | 80–130 | 69 |
Day X means the day of admission, and this patient was discharged on day X + 24.
Alb, albumin (g/dL); ALP, alkaline phosphatase (U/L); ALT, alanine aminotransferase (U/L); AST, aspartate aminotransferase (U/L); BNP, brain natriuretic peptide (pg/mL); BP, blood pressure (mmHg); BUN, blood urea nitrogen (mg/dL); Ca, serum calcium concentration (mg/dL); CHE, choline esterase (U/L); CK, creatine kinase (U/L); Cl, serum chloride concentration (mmol/L); Cr, creatinine (mg/dL); CRP, C‐reactive protein (mg/dL); eCCR, estimated creatinine clearance calculated by Cockcroft–Gault equation (mL/min); eGFR, estimated glomerular filtration rate calculated by creatinine‐based equation modified for Japanese patients with chronic kidney disease (mL/min/1.73m2); FBG, fasting blood glucose (mg/dL); Fe, serum iron concentration (μg/dL); Hb, hemoglobin concentration (g/dL); HDL, high‐density lipoprotein cholesterol (mg/dL); HR, heart rate (bpm); Ht, hematocrit (%); K, serum potassium concentration (mmol/L); LDH, lactate dehydrogenase (U/L); LDL, low‐density lipoprotein cholesterol (mg/dL); Mg, serum magnesium concentration (mg/dL); Na, serum sodium concentration (mmol/L); Plt, platelet (×104/μL); RBC, red blood cells (×104/μL); T. Bil, total bilirubin (mg/dL); T. Chol, total cholesterol (mg/dL); TG, triglyceride (mg/dL); TP, total protein (g/dL); UA, uric acid (mg/dL); WBC, white blood cells (/μL); Zn, serum zinc concentration (μg/dL).
HF is defined as a pathological state in which cardiac output is insufficient to meet the oxygen demands and metabolic needs of vital organs. The clinical events exacerbating HF are (i) sustained reduction of cardiac function; (ii) augmentation of cardiac workload; or (iii) the combination of both. The augmented cardiac workload is common, whereas cardiac dysfunction induced by electrolyte imbalance is rare as a practical etiology of HF. The present case was a senile patient with hypermagnesemia underlying HF. On admission, the serum Mg concentration was 5.1 mg/dL, and Mg oxide was replaced with sennoside immediately. Memantine might have exacerbated constipation and bradycardia. Mg acts as a natural calcium antagonist, exerting negative chronotropic and vasodilating actions. Bradyarrhythmia and hypotension under hypermagnesemia disappeared after the cessation of amlodipine, memantine and Mg oxide. This case strongly suggests that monitoring electrolytes and reviewing prescription are important for treating HF disclosed by bradyarrhythmia and hypotension.
The association of HF with Mg alteration is controversial. Large clinical trials showed the relationship between the serum Mg concentration and the prognosis in HF patients. The prospective randomized milrinone survival evaluation (PROMISE) study clarified that serum Mg is not an independent risk factor of all‐cause mortality in HF patients after adjustment of cofounders. 5 The Epleronone Post‐Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) study showed that Mg alterations have no association with clinical outcomes in patients with myocardial infarction complicated by HF. 6 However, hypermagnesemia, but not hypomagnesemia, was associated with cardiovascular and all‐cause mortalities in HF patients in the meta‐analysis. 7 These conflicting results are partly attributable to extents of Mg alterations; that is, the EPHESUS study defined hypomagnesemia and hypermagnesemia as serum Mg concentrations <0.66 mmol/L (1.58 mg/dL) and >1.10 mmol/L (2.64 mg/dL), respectively, 6 whereas these alterations were defined as serum Mg ≤1.5 mEq/L (1. 8 mg/dL) and ≥1.9 mEq/L (2.28 mg/dL) in the PROMISE study. 5
In conclusion, a senile hypertensive patient presented HF caused by bradyarrhythmia and hypotension under hypermagnesemia. Mg‐containing laxative in the gut acts as a reservoir of Mg in constipated patients. 8 Hypermagnesemia exacerbates HF by: (i) negative inotropic and chronotropic actions of Mg; and (ii) hypoperfusion of multiple organs induced by Mg‐induced excessive vasodilation. It is of clinical importance to monitor electrolytes, and to review prescription for prevention of hypermagnesemia worsening hemodynamics in senile patients with constipation and renal insufficiency.
Disclosure statement
The authors declare no conflict of interest.
Acknowledgements
All authors acknowledge the nursing, laboratory and rehabilitation staff taking care of this case. Open access funding was provided by Hara Doi Hospital, Fukuoka, Japan. (http://www.haradoi-hospital.com).
Eiraku K, Uozumi Y, Hieda M, Maruyama T, Nomura H. A senile case of heart failure associated with hypermagnesemia induced by magnesium‐containing laxative agent. Geriatr. Gerontol. Int. 2022;22:897–899. 10.1111/ggi.14478
Data availability statement
The data supporting the findings of this case report are available from the corresponding author upon reasonable request (tmaruyama@haradoi-hospital.com).
References
- 1. Swaminathan R. Magnesium metabolism and its disorders. Clin Biochem Rev 2003; 24: 47–66. [PMC free article] [PubMed] [Google Scholar]
- 2. Barbagallo M, Belvedere M, Dominguez LJ. Magnesium homeostasis and aging. Magnes Res 2009; 22: 235–246. 10.1684/mrh.2009.0187. [DOI] [PubMed] [Google Scholar]
- 3. William JH, Richards K, Danziger J. Magnesium and drugs commonly used in chronic kidney disease. Adv Chronic Kidney Dis 2018; 25: 267–273. 10.1053/j.ackd.2018.01.005. [DOI] [PubMed] [Google Scholar]
- 4. Yamaguchi H, Shimada H, Yoshita K et al. Severe hypermagnesemia induced by magnesium oxide ingestion: a case series. CEN Case Rep 2019; 8: 31–37. 10.1007/s13730-018-0359-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5. Eichhorn EJ, Tandon PK, DiBianco R et al. Clinical and prognostic significance of serum magnesium concentration in patients with severe chronic congestive heart failure: the PROMISE study. J Am Coll Cardiol 1993; 21: 634–640. 10.1016/0735-1097(93)90095-i. [DOI] [PubMed] [Google Scholar]
- 6. Martens P, Ferreira JP, Vincent J et al. Prognostic relevance of magnesium alterations in patients with a myocardial infarction and left ventricular dysfunction: insight from the EPHESUS trial. Eur Heart J Acute Cardiovasc Care 2022; 11: 148–159. 10.1093/ehjacc/zuab111. [DOI] [PubMed] [Google Scholar]
- 7. Angkananard T, Anothaisintawee T, Eursiriwan S et al. The association of serum magnesium and mortality outcomes in heart failure patients: a systematic review and meta‐analysis. Medicine 2016; 95: e5406. 10.1097/MD.0000000000005406. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8. Bokhari SR, Siriki R, Teran FJ, Batuman V. Fatal hypermagnesemia due to laxative use. Am J Med Sci 2018; 355: 390–395. 10.1016/j.amjms.2017.08.013. [DOI] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Data Availability Statement
The data supporting the findings of this case report are available from the corresponding author upon reasonable request (tmaruyama@haradoi-hospital.com).
